Back to Search Start Over

New Nitric Oxide Donor NCX 1443: Therapeutic Effects on Pulmonary Hypertension in the SAD Mouse Model of Sickle Cell Disease.

Authors :
Abid S
Kebe K
Houssaïni A
Tomberli F
Marcos E
Bizard E
Breau M
Parpaleix A
Tissot CM
Maitre B
Lipskaia L
Derumeaux G
Bastia E
Mekontso-Dessap A
Adnot S
Source :
Journal of cardiovascular pharmacology [J Cardiovasc Pharmacol] 2018 May; Vol. 71 (5), pp. 283-292.
Publication Year :
2018

Abstract

Nitric oxide (NO) donors may be useful for treating pulmonary hypertension (PH) complicating sickle cell disease (SCD), as endogenous NO is inactivated by hemoglobin released by intravascular hemolysis. Here, we investigated the effects of the new NO donor NCX1443 on PH in transgenic SAD mice, which exhibit mild SCD without severe hemolytic anemia. In SAD and wild-type (WT) mice, the pulmonary pressure response to acute hypoxia was similar and was abolished by 100 mg/kg NCX1443. The level of PH was also similar in SAD and WT mice exposed to chronic hypoxia (9% O2) alone or with SU5416 and was similarly reduced by daily NCX1443 gavage. Compared with WT mice, SAD mice exhibited higher levels of HO-1, endothelial NO synthase, and PDE5 but similar levels of lung cyclic guanosine monophosphate. Cultured pulmonary artery smooth muscle cells from SAD mice grew faster than those from WT mice and had higher PDE5 protein levels. Combining NCX1443 and a PDE5 inhibitor suppressed the growth rate difference between SAD and WT cells and induced a larger reduction in hypoxic PH severity in SAD than in WT mice. By amplifying endogenous protective mechanisms, NCX1443 in combination with PDE5 inhibition may prove useful for treating PH complicating SCD.

Details

Language :
English
ISSN :
1533-4023
Volume :
71
Issue :
5
Database :
MEDLINE
Journal :
Journal of cardiovascular pharmacology
Publication Type :
Academic Journal
Accession number :
29438213
Full Text :
https://doi.org/10.1097/FJC.0000000000000570